1. Home
  2. NLOP vs ALLO Comparison

NLOP vs ALLO Comparison

Compare NLOP & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NLOP

Net Lease Office Properties of Beneficial Interest

HOLD

Current Price

$19.83

Market Cap

293.3M

Sector

N/A

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.81

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NLOP
ALLO
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.3M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NLOP
ALLO
Price
$19.83
$1.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
12
Target Price
$46.00
$8.27
AVG Volume (30 Days)
340.2K
6.3M
Earning Date
02-27-2026
03-12-2026
Dividend Yield
96.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$115,901,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.45
$0.86
52 Week High
$34.53
$3.78

Technical Indicators

Market Signals
Indicator
NLOP
ALLO
Relative Strength Index (RSI) 42.98 58.49
Support Level $19.16 $1.56
Resistance Level $20.00 $1.84
Average True Range (ATR) 0.43 0.16
MACD 0.29 -0.01
Stochastic Oscillator 87.10 67.96

Price Performance

Historical Comparison
NLOP
ALLO

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: